PUBLICATIONS

BOOK CHAPTERS

1. Shute JK. Glycosaminoglycans and cytokine/growth factor interactions. In: Heparin- a 100 years on. Page CP, Mulloy B, Lever R, Eds. Springer-Verlag, 2012.

2. Shute JK. Induced sputum studies in cystic fibrosis. In: Atlas of induced sputum. Djukanovic R, Sterk P, Eds. Parthenon Publishing. 2004; 89-98.

3. Shute JK, Kelly M. Analysis of soluble mediators in the sputum fluid phase. In: Atlas of induced sputum. Djukanovic R, Sterk P, Eds. Parthenon Publishing. 2004; 35-52.

PEER REVIEWED JOURNALS

1. Brims FJH, Chauhan AJ, Higgins BR, Shute JK. Upregulation of the extrinsic coagulation pathway in acute asthma-a case study. J Asthma 2010, 47: 695-8.

2. Ulrich M, Worlitzsch D, Viglio S, Siegmann N, Iadarola P, Shute JK, Geiser M, Pier GB, Friedel G, Barr ML, Schuster A, Meyer KC, Ratjen F, Bjarnsholt T, Gulbins E, DÖring G. Alveolar inflammation in cystic fibrosis. J Cyst Fibrosis 2010; 9: 217-227.

3. Serisier DJ, Carroll MP, Shute JK, Young SA. Macrorheology of cystic fibrosis, chronic obstructive pulmonary disease & normal sputum. Respiratory Research 2009; 10:63.

4. Brims FJH, Chauhan AJ, Higgins B, Shute JK. Coagulation factors in the airways in moderate and severe asthma and the effect of inhaled steroids. Thorax, 2009; 64: 1037-1043.

5. Shur J, Nevell TG, Shute JK, Smith JR. The spray drying of unfractionated heparin: optimisation of the operating parameters. Drug Dev Ind Pharm 2008; 34: 559-68.

6. Shur J, Ewen RJ, Nevell TG, Smith AJ, Shute JK, Smith JR. Co-spray-dried unfractionated heparin with L-leucine as a dry powder inhaler mucolytic in cystic fibrosis. J Pharm Sci 2008; 97: 4857-68

7. Broughton-Head VJ, Smith JR, Shur J, Shute JK. Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics. Pulm Pharm Ther. 2007; 20: 708-717

8. Hilliard TN, Regamey N, Shute JK, Nicholson A, Alton EW, Bush A, Davies JC. Airway remodelling in children with cystic fibrosis, Thorax 2007; 62: 1074-1080.

9. Broughton-Head VJ, Shur J, Carroll MP, Smith JR, Shute JK. Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2007; 293: L1240-1249.

10. Perrio MJ, Ewen D, Trevethick MA, Salmon GP, Shute JK. Fibrin formation by wounded bronchial epithelial cell layers in vitro is essential for normal epithelial repair and independent of plasma proteins. Clin Exp Allergy 2007; 37: 1688-1700.

11. Serisier D, Shute JK, Hockey PM, Higgins B, Conway J, Carroll MP. Inhaled heparin in cystic fibrosis. Eur Respir J 2006; 27:354-358.

12. Paul K, Rietschel E, Ballmann M, Griese M, Worlitzsch D, Shute J, Chen C, Schink T, Doring G, Van Konigsbruggen S, Wahn U, Ratjen F. Effect of treatment with dornase alpha on airway inflammation in cystic fibrosis patients. Am J Respir Crit Care Med. 2004; 169: 719-725

13. Suri R, Marshall LJ, Wallis C, Metcalfe C, Shute JK, Bush A. Safety and use of sputum induction in children with cystic fibrosis. Pediatr Pulmonol 2003; 35: 309-313.

14. Suri R, Marshall LJ, Wallis C, Metcalfe C, Bush A, Shute JK. Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis. Am J Respir Crit Care Med. 2002, 166; 352-355

15. Perks B, Shute JK. 2000. DNA and actin bind and inhibit IL-8 function in cystic fibrosis sputa: in vitro effects of mucolytics. Am J Respir Crit Care Med, 162: 1767-72.

16. Louis R, Shute JK, Goldring K, Perks B, Djukanovic R. The effect of processing on inflammatory markers in induced sputum. Eur Resp J 1999; 13: 660-667.

17. Ramdin L, Perks B, Sheron N, Shute JK. Regulation of interleukin-8 binding and function by heparin and alpha2-macrogobulin. Clin Exp Allergy 1998; 28: 616-624.